Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear factor interleukin 3 regulated protein (NFIL3, E4BP4) is a basic leucine zipper (bZIP) transcription factor crucial for differentiation and survival of immune cells, modulation of circadian rhythms, and neuroprotection. Structurally, NFIL3 contains a bZIP DNA-binding domain that dimerizes via a leucine zipper, binding specifically to the TTACGTAA DNA motif to regulate gene expression. NFIL3 represses genes involved in apoptosis, aiding cell survival, and has established roles in cancer progression (notably breast and colon cancer), as well as neuroprotection in models of ALS and other neurodegenerative diseases. It is also involved in the differentiation and maintenance of innate lymphoid cells (ILCs), which are key regulators of immune responses. While there is significant therapeutic interest, NFIL3 remains largely "undruggable" by conventional means, though approaches targeting its dimerization or DNA binding interfaces are in early investigation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear factor interleukin 3 regulated protein (NFIL3).